International Journal of Women's Health Dovepress Update on Denosumab in the Management of Postmenopausal Osteoporosis: Patient Preference and Adherence
暂无分享,去创建一个
[1] J. Reginster,et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study , 2015, Osteoporosis International.
[2] P. Geusens,et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study , 2015, Osteoporosis International.
[3] Jacques P. Brown,et al. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. , 2015, The Journal of clinical endocrinology and metabolism.
[4] P. Camacho,et al. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[5] Jacques P. Brown,et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study , 2014, Osteoporosis International.
[6] P. Farahmand,et al. Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile , 2014, Rheumatology International.
[7] C. Roux,et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate , 2014, Osteoporosis International.
[8] R. Horne,et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study , 2014, Menopause.
[9] N. Yurgin,et al. Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US , 2013, Applied Health Economics and Health Policy.
[10] C. Benhamou,et al. Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial , 2013, Obstetrics and gynecology.
[11] C. Dirksen,et al. Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporotic women , 2013, Expert review of pharmacoeconomics & outcomes research.
[12] R. Goeree,et al. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada , 2012, Journal of medical economics.
[13] J. Nho,et al. Persistence with intravenous zoledronate in elderly patients with osteoporosis , 2012, Osteoporosis International.
[14] K. Saag,et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population , 2012, Arthritis care & research.
[15] K. Kostev,et al. Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. , 2012, International journal of clinical pharmacology and therapeutics.
[16] Tianjing Li,et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.
[17] E. Barrett-Connor,et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™ , 2012, Osteoporosis International.
[18] R. Horne,et al. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] M. Hiligsmann,et al. Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium , 2011, PharmacoEconomics.
[20] N. Freemantle,et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.
[21] N. Freemantle,et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate , 2011, Osteoporosis International.
[22] T. Rachner,et al. Osteoporosis: now and the future , 2011, The Lancet.
[23] J. Kanis,et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis , 2011, Osteoporosis International.
[24] S. Lee,et al. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009 , 2011, Osteoporosis International.
[25] I. Imaz,et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis , 2010, Osteoporosis International.
[26] R. Horne,et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass , 2010, Osteoporosis International.
[27] M. Hiligsmann,et al. Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications , 2010, Calcified Tissue International.
[28] Jacques P. Brown,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[30] R. O’Keefe,et al. Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] J. S. San Martin,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.
[32] H. Ward,et al. Predictive Validity of a Medication Adherence Measure in an Outpatient Setting , 2008, Journal of clinical hypertension.
[33] P. Miller,et al. Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[34] E. Badamgarav,et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. , 2007, Mayo Clinic proceedings.
[35] R. Recker,et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. , 2007, Bone.
[36] R. Lindsay,et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. , 2007, Bone.
[37] J. Reginster,et al. Adherence, patient preference and dosing frequency: understanding the relationship. , 2006, Bone.
[38] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[39] S. Cummings,et al. Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.
[40] Jacques P. Brown,et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. , 2014, Bone.
[41] Anuja Roy,et al. Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[42] M. Atkinson,et al. Health and Quality of Life Outcomes , 2004 .